Connect with us

News

New tool could prevent 150,000 age-related falls a year in EU alone

Published

on

The man behind an innovative exercise and rehabilitation system to screen patients at risk of serious falls, believes it will “revolutionise” the way the primary care sector deals with what has become a massive global problem linked to ageing.

Tim Henson has spent the last decade and hundreds of thousands of pounds developing the Formula Motion falls prevention screening machine.

The UK-based product developer, who has already made a name for himself as the inventor of novel patient lifting devices and a curved stairlift manufactured and sold by a British company, maintains Formula Motion could help make the world an easier place to live for those susceptible to falls, and even help spot the early signs of Alzheimer’s, whose symptoms can include loss of balance and coordination.

Mr Henson said Formula Motion –  which has already been granted patents in the US, EU and UK – could also be used for stroke rehabilitation; treating Parkinson’s, multiple sclerosis, and muscular dystrophy patients amongst others; by elite athletes, gyms and health clubs; in sports injury and physiotherapy clinics; and to help combat virtual reality sickness, where over-exposure to VR technology can lead to feelings of motion sickness, dizziness, and nausea.

Aston University in Birmingham in the UK and the ExtraCare Charitable Trust – a major retirement village group – have already been involved in early testing for falls prevention, while Loughborough University has helped with the elite sports side.

Formula Motion is still in the working prototype phase with Mr Henson looking to raise £1.4m to finalise the design of a production model, do further testing, and gain safety approval. But a US distributor has already been identified.

Mr Henson told Agetech World: “Formula Motion is a truly dynamic way of screening for those at risk of falling. This is confirmed by our technology being patented in the US, UK and key European countries. Basically, our new care pathway will revolutionise the way we deal with the massive worldwide problem of falls in the older population.

“With the time and the money I have already put into this, I am confident that Formula Motion will have a big impact on the way older patients are dealt with in primary care not just in the UK, but around the world, improving the targeting of treatments and fall prevention strategies which in turn will help reduce hospital admissions and speed up recovery times.”

According to the World Health Organisation, the share of the global population aged over 60 will stand at 1.4bn by 2030.

Older people are more likely to have a fall because the natural ageing process can cause balance, vision and hearing problems as well as muscle deterioration. Medical issues and certain drugs can also increase the risk of tripping, stumbling, slipping and collapsing.

Adults over the age of 60 suffer the greatest number of fatal falls, with World Health Organisation figures suggesting 684,000 people die globally every year as a result – the second leading cause of unintentional injury deaths.

More than 37m falls annually are severe enough to need medical attention.

In the EU and UK alone one in three older people will suffer a fall, resulting in 3.5m fractures costing £40bn in treatment costs. Of these, 33% with a hip fracture will die within 12 months.

The World Health Organisation has proposed a number of prevention strategies, including education, training, and creating safer environments, as well as “prioritising fall-related research and establishing effective policies to reduce risk.”

The Formula Motion machine.

Mr Henson believes Formula Motion could prevent 150,000 falls annually just in Europe, saving not only lives but €1.8bn.

He said: “Formula Motion could have a massive impact on the way older patients are managed in the primary care setting, improving fall prevention strategies and the targeting of treatment.”

There are other devices currently on the market to predict and prevent serious falls. But Mr Henson claims none offer the features and benefits of his system.

Formula Motion works like a ‘wobble board’. Users can either move the platform themselves by body pressure, or the machine can do the work for them. It is capable of switching instantly between both modes. Mr Henson said: “These features are unique and give the ability to give a truly dynamic balance assessment and falls prevention screening.”

Operated by an intuitive touch screen, users can sit, stand, kneel or lie on the platform. It can raise, lower and tilt in all directions, and combine to give sophisticated movements.

Set programmes can be run to exercise specific combinations of muscles, or to enhance skills for a particular rehabilitation or sport.

The user or a medical professional can also create programmes tailored to particular needs.

Mr Henson said Formula Motion’s hybrid design “is unique and adds a whole new dimension to the fields of rehabilitation, performance training, exercise and virtual reality.”

It is the intention to target the falls prevention market first, and then the rehabilitation sector, elite sports, fitness gyms and virtual reality.

Tim Henson – inventor, founder and CEO of Formula Motion.

Mr Henson fell into working in the medical and disability world 20 years ago when he developed a new kind of lifting frame for a friend who was a wheelchair user.

“Once you do one thing, you start to do others,” he explained. “I then developed a stair lift and got involved in what you might call invasive medical products. I’ve designed products for caesarean births and bowel operations.

“People come to me and say, ‘we’re consultants in such and such medical field, we need a device that can do so and so.’ They explain their need and I go off and do the engineering.

“The age market place probably came to mind about 10 years ago. We all have relatives and friends who are elderly and they have a fall. If they’re in their 70s or 80s, they might break a hip and, if we’re really blunt about it, a fall at that age can often be the start of their demise.

“Falls are the unknown pandemic. When you think about the number of falls and the deaths that result from them, it’s an enormous problem.”

He continued: “What struck me all those years ago is that people often don’t realise as they get older that they are losing their balance. It sounds a little corny, but I thought why don’t we screen everyone when they get to say 70, like we screen for breast cancer, and we can determine their balance ability compared with the norm.

“If everyone was screened and there was a quick way of doing that, the minimum benefit would be that someone would go home from that screening aware that their balance wasn’t as good as it once was. So that person may say, ‘you know what, I won’t go up the ladder to paint the house anymore because I now know my balance isn’t as good.’

“Often screening alerts people to a problem and they look after themselves more.”

Mr Henson said other reasons for screening is that once it is known that someone’s balance isn’t as good as it should be, investigations can begin to determine why. “It could be as simple as an ear or muscular issue, or it could alert doctors to it not just being an age thing, but a sign of something else that needs investigating.

“It was from this that I had the vision about developing a balance machine that could prevent injury, rehabilitate and save lives.

“Our vision is for a world where the catastrophic effects of falls on the elderly, including loss of independence and loss of life, are a distant memory.”

News

Mole rat gene extends mouse lifespan

Published

on

A mole rat gene inserted into mice extended lifespan and improved health, findings that may point to new ways of supporting healthier ageing.

The gene increased production of a large form of hyaluronan, a naturally occurring gel-like substance between cells that helps tissue repair and cell-to-cell communication.

Mice carrying the naked mole rat version of the gene showed an approximately 4.4 per cent increase in median lifespan, alongside multiple markers of healthier ageing.

Naked mole rats have become a focus of ageing research because they combine an exceptional lifespan with unusual resistance to many age-linked diseases, including cancer.

Researchers at the University of Rochester traced part of that resilience to hyaluronan.

The molecule’s effects depend on its size: large forms are often linked to anti-inflammatory and tissue-protective behaviour, while smaller fragments can act as danger signals that increase inflammation.

Vera Gorbunova, professor of biology and medicine at the University of Rochester in the US, said: “Our study provides a proof of principle that unique longevity mechanisms that evolved in long-lived mammalian species can be exported to improve the lifespans of other mammals.”

The engineered mice were better protected against both spontaneous tumours and chemically induced skin cancer.

They also showed reduced inflammation across tissues, a notable finding because persistent low-grade inflammation, sometimes called inflammaging, is widely seen as one of the central drivers of age-related decline.

The research also linked the large form of hyaluronan to age-related gut health. As animals age, the gut barrier can become leakier, allowing inflammatory triggers to pass into the bloodstream.

The engineered mice showed protection against this deterioration.

Follow-up work found abundant high-molecular-mass hyaluronan across multiple species of subterranean mammals, often absent in closely related above-ground species, suggesting it may be part of a broader evolutionary toolkit for surviving long lives under harsh conditions.

The team said gene transfer is not the end goal. Gorbunova said: “It took us 10 years from the discovery of HMW-HA in the naked mole rat to showing that HMW-HA improves health in mice.”

“Our next goal is to transfer this benefit to humans.”

Two practical routes are being pursued: increasing production of the large form of hyaluronan, or slowing its breakdown.

Andrei Seluanov, who co-leads the research, said: “We already have identified molecules that slow down hyaluronan degradation and are testing them in pre-clinical trials.”

One candidate identified through screening is delphinidin, a plant pigment found in various fruits and vegetables.

In tests, it was found to increase levels of the large form of hyaluronan in cells and mouse tissues, reduce migration and invasion in multiple cancer cell lines, and suppress melanoma metastasis in mice.

However, the researchers acknowledged the approach has limits. A later study found that mice expressing the naked mole rat gene showed improvements in several late-life health measures but did not show protection from age-related hearing loss, suggesting some organs may be less reachable by this pathway than others.

The Rochester team said turning these findings into human therapies will likely depend on precision: maintaining the right molecular form of hyaluronan, targeting the right balance of production versus breakdown, and monitoring carefully for trade-offs as different tissues respond in different ways.

Continue Reading

News

AI can predict Alzheimer’s with almost 93% accuracy, researchers say

Published

on

Alzheimer’s AI can predict the disease with nearly 93 per cent accuracy using more than 800 brain scans, researchers say.

The system identified anatomical changes in the brain linked to the onset of the most common form of dementia, a condition that gradually damages memory and thinking.

The findings build on years of research suggesting AI could help spot early Alzheimer’s risk, predict disease and identify patients whose condition has not yet been diagnosed.

Benjamin Nephew, an assistant research professor at the Worcester Polytechnic Institute in Massachusetts, said: “Early diagnosis of Alzheimer’s disease can be difficult because symptoms can be mistaken for normal ageing.

“We found that machine-learning technologies, however, can analyse large amounts of data from scans to identify subtle changes and accurately predict Alzheimer’s disease and related cognitive states.”

The study used MRI scans, a type of detailed brain imaging, from 344 people aged 69 to 84.

The dataset included 281 scans showing normal mental function, 332 with mild cognitive impairment, an early stage of memory and thinking decline, and 202 with Alzheimer’s.

The scans covered 95 of the brain’s nearly 200 distinct regions and used an AI algorithm to predict patients’ health.

Being able to use AI to help diagnose Alzheimer’s earlier could give patients and doctors crucial time to prepare and potentially slow the progression of the disease.

The analysis showed that one of the top predictive factors was brain volume loss, or shrinkage, in the hippocampus, which helps form memories, the amygdala, which processes fear, and the entorhinal cortex, which helps provide a sense of time.

This pattern held across age and sex, with both men and women aged 69 to 76 showing volume loss in the right part of the hippocampus, suggesting it may be an important area for early diagnosis, the researchers noted.

However, the research also found that the way brain regions shrink differs by sex.

In females, volume loss occurred in the brain’s left middle temporal cortex, which is involved in language and visual perception. In males, it was mainly seen in the right entorhinal cortex

The researchers believe this could be linked to changes in sex hormones, including the loss of oestrogen in women and testosterone in men.

These conclusions could help improve methods of diagnosis and treatment going forward, Nephew said.

More than 7.2m Americans are living with Alzheimer’s, according to the Alzheimer’s Association.

More research is being done to reveal other impacting factors.

Nephew said: “The critical challenge in this research is to build a generalisable machine-learning model that captures the difference between healthy brains and brains from people with mild cognitive impairment or Alzheimer’s disease.”

Continue Reading

News

Vision implant firm raises US$230m

Published

on

A vision implant firm has raised US$230m as it seeks approval in Europe and the US for a device that restored sight in a small clinical trial.

The Alameda, California-based startup said the funding would support commercialisation of its Prima device.

It said an upcoming launch is planned in Europe and that it would become the first brain computer interface company to have a vision restoration device on the market.

A clinical trial in Europe found the small implant could work as artificial photoreceptors in the retina to restore functional central vision.

The implant is placed under the retina to replace the function of light-sensitive cells lost to disease. A special pair of glasses with an embedded camera and infrared projector sends light signals to the implant.

The study assessed the system in people with advanced dry age-related macular degeneration.

Of the 38 patients who received an implant, 32 were assessed at 12 months. Results showed the device led to a clinically meaningful improvement in visual acuity in 26 people.

The patients were able to read letters, numbers and words, according to the company.

Science Corporation said it has submitted a CE mark application to the European Union and applied to the US Food and Drug Administration for regulatory approval.

Darius Shahida, chief strategy officer, said: “Our imperative is to become the first BCI company to scale and achieve profitability.”

Founded in 2021, the company has now raised about US$490m in total. It said it is expanding its clinical trial programme to include other retinal diseases, such as Stargardt disease and retinitis pigmentosa.

The Series C round included existing investors Khosla Ventures, Lightspeed Venture Partners, Y Combinator, IQT and Quiet Capital.

Science Corporation said demand for the round exceeded its capital needs, with funds also earmarked for expanding research, manufacturing infrastructure and operations.

Continue Reading

Trending

Agetech World